At a glance
- Originator AstraZeneca
- Class Anti-ischaemics; Neuroprotectants; Nootropics
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 10 Mar 1999 Discontinued-Preclinical for Neurological disorders (Prevention) in United Kingdom (Unknown route)
- 09 Dec 1996 No-Development-Reported for Neurological disorders (Prevention) in United Kingdom (Unknown route)